[Studies to the in-vitro-effectiveness of Spectacillin (author's transl)]
Abstract:
In this study the sensibility of important disease germs of a clinical and an ambulatory test material has been investigated to the substances "Epicillin" and "Ampicillin". Thereby could be found that 67% (43%) of the E. coli and 55% (36%) of the proteus type, as well as 96% (96%) of the enterococcus type of the ambulatory (clinical) test material were sensitive to Epicillin and Ampicillin. Staphylococcus not producing penicillinase, were well-sensitive, while staphylococcus producing penicillinase, contrarily showed to be insensitive. Salmonellae proved to be well-sensitive up to 97%, and the rest left was limited sensitive. The minimal inhibitory concentration (MIC) resulted in favourable findings for enterococcus, staphylococcus aureus and salmonellae; at a corresponding sensibility the same is valid for E. coli and the proteus. The investigations carried out in-vitro, reveal an equal effectiveness of Epicillin and Ampicillin.
Insights
Epicillin and Ampicillin show equal effectiveness against common bacteria like E. coli and Salmonella. Both antibiotics were effective against Enterococcus and sensitive Staphylococcus strains in vitro.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Antibiotic resistance is a growing concern in clinical and ambulatory settings.
- Understanding the efficacy of broad-spectrum antibiotics like Epicillin and Ampicillin against prevalent pathogens is crucial.
Purpose of the Study:
- To investigate the in vitro sensitivity of key clinical and ambulatory disease-causing bacteria to Epicillin and Ampicillin.
- To compare the effectiveness of Epicillin and Ampicillin against various bacterial strains, including E. coli, Proteus, Enterococcus, Staphylococcus, and Salmonella.
Main Methods:
- In vitro susceptibility testing was performed on clinical and ambulatory bacterial isolates.
- Bacterial strains tested included E. coli, Proteus, Enterococcus, Staphylococcus (penicillinase-producing and non-producing), and Salmonella.
- Minimal Inhibitory Concentration (MIC) was determined for key bacterial groups.
Main Results:
- High sensitivity rates were observed for Enterococcus (96%) and Salmonella (up to 97%) for both Epicillin and Ampicillin.
- Epicillin and Ampicillin demonstrated significant efficacy against E. coli (67% sensitive) and Proteus (55% sensitive).
- Penicillinase-producing Staphylococcus strains were insensitive, while non-producing strains were sensitive; MIC values were favorable for Enterococcus, Staphylococcus aureus, and Salmonella.
Conclusions:
- Epicillin and Ampicillin exhibit comparable in vitro effectiveness against a range of clinically significant bacteria.
- The study highlights the importance of distinguishing between penicillinase-producing and non-producing Staphylococcus strains when considering these antibiotics.
- Both antibiotics are effective options for treating infections caused by sensitive E. coli, Proteus, Enterococcus, and Salmonella.
